Finesse Solutions, a manufacturer of measurement and control solutions for life sciences process applications, has announced a partnership agreement with Spectra Automation, a control system integrator in Massachusetts.
The movement toward transparency is global, touching almost every aspect of society. Whether the...
Acorn Applications, a developer of cloud-based analytic clinical research solutions, announced...
Pluristem Therapeutics today announced that the FDA has reviewed its PLacental eXpanded (PLX)...
B&W Tek and LabWare have joined together to distribute a pre-configured Raman spectroscopy template solution that allows for seamless and easy automation of data acquisition from B&W Tek’s NanoRam handheld Raman spectrometer into LabWare’s Enterprise Laboratory Platform.
Delaware has 17 condemned prisoners facing the death penalty, but no means of executing any of them.
Eisai and Biogen Idec announced have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401.
The right combination of equipment, capsule, and formulation can bolster yields, speed up filling, and cut downtime for faster market delivery and higher profits.
Enhanced Pharmaceutical Drug Classification System Now Available via The United Nations Standard Products and Services CodeMarch 4, 2014 11:53 am | News | Comments
The United Nations Standard Products and Services Code® (UNSPSC®), managed by GS1 US, now includes an enhanced global product classification system for active pharmaceutical drugs worldwide.
Stanford University is working with K-PAX Pharmaceuticals to perform a double-blind, placebo-controlled trial to evaluate the safety and efficacy of a currently available FDA-approved medication co-administered with a novel mitochondrial support product in order to identify a safe and effective treatment for the chronic fatigue and concentration disturbance symptoms.
Xenetic Biosciences, a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced the opening of its new corporate headquarters and research and development facility in Lexington, MA.
Dynavax Technologies Corp. has announced a $5.4 million milestone payment from its collaborator, AstraZeneca.
Theravance announced today that its plan to separate its businesses into two independent, publicly traded companies is now expected to be completed during the second quarter 2014.
New development technologies, expanded contract manufacturing and service capabilities, as well as innovative equipment investment strategies highlight leading practices from the best in pharmaceutical processing comprise the 2014 Pharmaceutical Processing Facility Excellence Award winners.
Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis InfectionsFebruary 24, 2014 8:01 am | News | Comments
Cellceutix Corporation has selected Dr. Reddy's Custom Pharmaceutical Services (CPS), part of the Pharmaceutical Services and Active Ingredients (PSAI) business unit of Dr. Reddy's Laboratories Ltd. for the formulation of the company's defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections.
Nuevolution A/S has entered an exclusive license agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development.
GNC, the largest specialty retailer of nutritional supplements in the world, is respected for its focus on quality. They rely on their subsidiary, Nutra Manufacturing, to apply their “quality first” principle to manufacturing. Over the years, Nutra has turned to Symetix® for high performance optical inspection systems that verify product quality.
The new five-year agreement, which extends through March 2019, creates efficiencies for both companies by leveraging the strength of Rite Aid as one of the leading national drugstore chains in the United States, and McKesson as a leader in pharmaceutical sourcing and supply chain management.
The health care products company Mallinckrodt is buying Cadence Pharmaceuticals for about $1.21 billion in a bid to strengthen its specialty drugs unit. Cadence, based in San Diego, focuses on the commercialization of products for use in hospitals.
UPS said Tuesday that it has completed its acquisition of Polar Speed, a company that helps deliver temperature-sensitive pharmaceutical supplies in the United Kingdom. Financial terms were not disclosed.
Merck and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes.
NASA has signed two patent license agreements with GRoK Technologies LLC of Houston to help develop novel biotechnology approaches that could have multiple applications in space and on Earth. The agreements are the results of the agency's Technology Transfer Program, which helps open up NASA's research and technology to the public for use and development.
Jazz Pharmaceuticals today announced that it has commenced construction of a manufacturing and development facility to be located on a 17-acre site in Monksland, County Roscommon, approximately 75 miles east of the company's Dublin headquarters. This is the first manufacturing facility to be built by Jazz Pharmaceuticals.
AbbVie has announcesd a US$320 million [approximately S$400 million] investment to establish operations in Singapore for small molecule and biologics active drug substance manufacturing.
Pfizer announced today that it has agreed with Merck to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.
The National Institutes of Health Director Francis Collins explained a breakthrough venture between private and public entities to find a cure for complex disorders such as diabetes, Alzheimer's Disease, and other illnesses connected to the human genome.
Actavis plc has announced a realignment of its global strategic business structure to maximize the company's position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth.
Abbott Laboratories is closing one of its manufacturing plants in the Puerto Rico town of Barceloneta next year, delivering another blow to the U.S. territory's once-thriving pharmaceutical sector, officials said Thursday.
Baxter International has restructured its ongoing agreement with Xenetic Biosciences, for the development of BAX 826, a recombinant Factor VIII treatment for hemophilia A under investigation to assess its potential to extend the half-life and duration of effectiveness.
- Page 1